Quantcast
Last updated on April 17, 2014 at 9:28 EDT

Latest Æterna Zentaris Stories

2012-11-07 08:27:35

QUEBEC CITY, Nov. 7, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its third quarter 2012 financial and operating results on Tuesday, November 13, 2012, after market close. The Company will host a conference call the next morning, Wednesday, November 14, 2012 at 8:30 a.m. (Eastern Time), to discuss these results. Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Newsroom" section, or...

2012-11-01 07:31:01

QUÉBEC CITY, Nov. 1, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its Director of Preclinical Development, Babette Aicher, PhD, will be making a poster presentation on preclinical results for disorazol Z cytotoxic conjugates, such as AEZS-125, in ovarian cancer, at the upcoming 24(th) EORTC-NCI-AACR (ENA) Symposium on "Molecular Targets and Cancer Therapeutics", which will be held November 6-9, 2012 in...

2012-10-22 07:28:57

QUÉBEC CITY, Oct. 22, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that on October 19, 2012, NASDAQ notified the Company that it has regained compliance with Rule 5450(a)(1), which requires a minimum bid price of $1.00 for continued listing on the NASDAQ Global Market. Commenting on the announcement, Juergen Engel, Ph.D., President and Chief Executive Officer, stated: "We are pleased that we have been able...

2012-10-18 07:25:37

QUEBEC CITY, Oct. 18, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that Phase 3 results for its ghrelin agonist, AEZS-130, show that it has promise as a safe and simple oral diagnostic test for adult growth hormone deficiency (AGHD), with accuracy comparable to available testing procedures. Results were presented earlier today by George R. Merriam, MD, Director of the Clinical Study Unit at the VA Puget Sound Health Care...

2012-10-17 07:27:59

QUÉBEC CITY, Oct. 17, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the closing of its previously announced public offering of 6.6 million units (the "Offering") generating net proceeds of US$15.2 million, with each unit consisting of one common share and 0.45 of a warrant to purchase one common share, at a purchase price of US$2.50 per unit. Each warrant is exercisable for a period of five years at...

2012-10-12 07:23:23

QUÉBEC CITY, Oct. 12, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the pricing of its previously announced public offering of 6.6 million units (the "Offering"), with each unit consisting of one common share and 0.45 of a warrant to purchase one common share, at a purchase price of US$2.50 per unit. Each warrant will be exercisable for a period of five years following the issuance thereof at an exercise price...

2012-10-10 07:27:48

QUÉBEC CITY, Oct. 10, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that George R. Merriam, MD, Director of the Clinical Study Unit at the VA Puget Sound Health Care System, and Professor of Medicine at the University of Washington, Seattle and Tacoma, WA, will give an oral presentation on AEZS-130, Aeterna Zentaris' ghrelin agonist, at the 6(th) International Congress of the Growth Hormone Research (GRS) and...

2012-10-03 02:27:05

Common shares will begin trading on a consolidated and split-adjusted basis on October 5, 2012 QUÉBEC CITY, Oct. 3, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the issued and outstanding common shares of the Company ("Common Shares") have been consolidated (the "Consolidation") on a six (6) to one (1) basis effective as of October 2, 2012. The purpose of the Consolidation is to enable the...

2012-09-26 10:24:02

QUÉBEC CITY, QC, Sept. 26, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that it continues to expect to file a New Drug Application (NDA) early next year, for its oral ghrelin agonist, AEZS-130, as a diagnostic test for adult growth hormone deficiency (AGHD), after receiving notification from the United States Food and Drug Administration (FDA) that Fast Track designation had not been granted. Juergen...

2012-09-26 02:25:57

QUÉBEC CITY, Sept. 26, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its Senior Vice President and CFO, Dennis Turpin, CPA CA, will be presenting a corporate overview at BioContact on Wednesday, October 3, 2012, at 2 pm (Eastern), in the Grande-Allée Room of the Château Laurier Hotel in Québec City, Canada. About Aeterna Zentaris Aeterna Zentaris is an oncology...